Many promising peptides fail because they degrade too easily. This limits their usefulness in drug design and creates ...
The U.S. Peptide Therapeutics Retail Market offers growth opportunities driven by increased healthcare spending and demand ...
As of Monday, November 10, Mesa Laboratories, Inc.’s MLAB share price has surged by 5.38%, which has investors questioning if ...
Imagine a country facing rising tensions with its neighbors. In a small research lab that looks no different from hundreds of ...
Susan Lois Hamilton, chair of the Department of Integrated Physiology, received her Ph.D. in biophysics from the University ...
Divi's Laboratories reported a strong revenue growth of 17% to ₹2,860 crore and a net profit increase of 35% to ₹689 crore ...
Key PointsThe composition and diversity of the gut microbiome is associated with sleep quality and duration in animal models ...
Novo Nordisk has reported the mixed midphase results behind its push to enter a heart disease market s | Novo Nordisk has reported the mixed midphase results behind its push to enter a heart disease ...
NDTV Profit on MSN
Stock Picks Today: Swiggy, Bajaj Auto, Apollo Hospitals, Britannia, Nykaa, Trent On Brokerage Radar
In addition, Goldman Sachs has raised India back to an Overweight position, expecting a 14% upside with an end-2026 NIFTY ...
CU Anschutz researchers uncovered a link between a type of mucosal immune cell and gut inflammation, finding that the cells ...
Pfizer and Novo Nordisk seem to want Metsera bad. Analysts are wondering, though: is the obesity biotech really worth this much effort?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback